Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the month of May 2024, with the report dated May 7, 2024. The filing serves to disseminate a press release regarding clinical study results for the Company's ProSense® cryoablation system.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical data and does not contain financial statements or operational metrics.
Material Changes
The primary material update is the announcement of independent study results from Japan. The study demonstrated a zero (0%) local recurrence rate for breast cancer five years following treatment with IceCure's ProSense® system. This data adds to the Company's global portfolio of positive clinical outcomes.
Guidance, Outlook, and Risks
The press release incorporates "Forward Looking Statements" by reference into the Company's Registration Statements on Form F-3 and Form S-8. The filing does not provide specific numerical guidance, management commentary on financial outlook, or a detailed list of risks within the text of this specific 6-K form, other than the standard incorporation of forward-looking language.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed study methodology and patient cohort sizes.
- Review the incorporated "Forward Looking Statements" in the referenced Form F-3 and Form S-8 registration statements for specific risk factors.
- Confirm the regulatory status of ProSense® in Japan and other key markets to assess commercialization timelines.
- Check subsequent filings for any financial impact or strategic shifts resulting from these clinical results.